Core Insights - Organon has decided to discontinue the clinical development of the drug candidate OG-6219 following the results of a Phase 2 clinical study that did not show improvement in endometriosis-related pain compared to placebo [1][2]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on identifying and developing breakthrough medical innovations in the Nordic region [5][6]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases and is led by a team of investment professionals with a strong track record [7]. Financial Implications - Prior to the announcement, Karolinska Development estimated the risk-adjusted net present value (rNPV) of future cash flows from earn-out payments at SEK 76.2 million. The company recognizes the need for an impairment if Organon discontinues the project, with final impairment details to be presented in the interim report for Q2 2025 [4].